First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008

Sunitinib is now a standard first-line therapy for metastatic clear-cell kidney cancer. This paper focuses on interpretation of the overall survival data presented at the 2008 annual meeting of the American Society of Clinical Oncology from the pivotal phase iii trial comparing sunitinib with interf...

Descripción completa

Detalles Bibliográficos
Autor principal: Wood, L.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687808/
https://www.ncbi.nlm.nih.gov/pubmed/19478904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687808/
https://www.ncbi.nlm.nih.gov/pubmed/19478904

Ejemplares similares